ArticleThe New England journal of medicine2006
Microscopic-observation drug-susceptibility assay for the diagnosis of TB.
Article in The New England journal of medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 177 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
177 citing papers in PubMed, 3 syntheses or guidelines pooled it, 475 citations in OpenAlex.
- Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis.BMC infectious diseases · 2013Pooled it
- Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.The Cochrane database of systematic reviews · 2013Pooled it
- Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis.BMC infectious diseases · 2009Pooled it
- MPT64 patch test for the diagnosis of active pulmonary tuberculosis: a randomised controlled trial in Peru.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2018Trial
- A Controlled Study of Tuberculosis Diagnosis in HIV-Infected and Uninfected Children in Peru.PloS one · 2015Trial
- Trial
- Trial
- Characteristics, Treatment Strategies, and Long-term Health Outcomes of People With Bedaquiline-resistant Tuberculosis in Karakalpakstan, Uzbekistan-A Retrospective Cohort Study.Open forum infectious diseases · 2026Article
- Article
- The Recent Development in the Diagnosis ofSmart medicine · 2025Review
- Phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG in 12 hours.Nature communications · 2025Article
- Deep learning-based framework for Mycobacterium tuberculosis bacterial growth detection for antimicrobial susceptibility testing.Computational and structural biotechnology journal · 2025Article
- QMAC-DST for Rapid Detection of Drug Resistance in Pulmonary Tuberculosis Patients: A Multicenter Pre-Post Comparative Study.Journal of clinical medicine · 2024Article
- Prison as a driver of recent transmissions of multidrug-resistant tuberculosis in Callao, Peru: a cross-sectional study.Lancet regional health. Americas · 2024Article
- Extracellular vesicles in bacterial and fungal diseases - Pathogenesis to diagnostic biomarkers.Virulence · 2023Review
- QuantitativeJournal of clinical microbiology · 2023Article
- An inflammation-related gene landscape predicts prognosis and response to immunotherapy in virus-associated hepatocellular carcinoma.Frontiers in oncology · 2023Article
- Evaluation of three alternatives cost-effective culture media for Mycobacterium tuberculosis detection and drug susceptibility determination using the microscopic observation drug susceptibility (MODS) assay.Tuberculosis (Edinburgh, Scotland) · 2022Article
- Tools to Alleviate the Drug Resistance inMolecules (Basel, Switzerland) · 2022Review
- Evaluation of Mutations Related to Streptomycin Resistance in Mycobacterium tuberculosis Clinical Isolates.Current microbiology · 2022Article
117 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
15 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundNew diagnostic tools are urgently needed to interrupt the transmission of tuberculosis and multidrug-resistant tuberculosis. Rapid, sensitive detection of tuberculosis and multidrug-resistant tuberculosis in sputum has been demonstrated in proof-of-principle studies of the microscopic-observation drug-susceptibility (MODS) assay, in which broth cultures are examined microscopically to detect characteristic growth.
methodsIn an operational setting in Peru, we investigated the performance of the MODS assay for culture and drug-susceptibility testing in three target groups: unselected patients with suspected tuberculosis, prescreened patients at high risk for tuberculosis or multidrug-resistant tuberculosis, and unselected hospitalized patients infected with the human immunodeficiency virus. We compared the MODS assay head-to-head with two reference methods: automated mycobacterial culture and culture on Löwenstein-Jensen medium with the proportion method.
resultsOf 3760 sputum samples, 401 (10.7%) yielded cultures positive for Mycobacterium tuberculosis. Sensitivity of detection was 97.8% for MODS culture, 89.0% for automated mycobacterial culture, and 84.0% for Löwenstein-Jensen culture (P<0.001); the median time to culture positivity was 7 days, 13 days, and 26 days, respectively (P<0.001), and the median time to the results of susceptibility tests was 7 days, 22 days, and 68 days, respectively. The incremental benefit of a second MODS culture was minimal, particularly in patients at high risk for tuberculosis or multidrug-resistant tuberculosis. Agreement between MODS and the reference standard for susceptibility was 100% for rifampin, 97% for isoniazid, 99% for rifampin and isoniazid (combined results for multidrug resistance), 95% for ethambutol, and 92% for streptomycin (kappa values, 1.0, 0.89, 0.93, 0.71, and 0.72, respectively).
conclusionsA single MODS culture of a sputum sample offers more rapid and sensitive detection of tuberculosis and multidrug-resistant tuberculosis than the existing gold-standard methods used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.